Group 1 - Dr. Reddy's Laboratories Ltd. announced the acquisition of the anti-vertigo drug 'Stugeron' from Johnson & Johnson affiliate Janssen Pharmaceutica NV for $50.5 million (Rs 445 crore) [1] - The acquisition includes the 'Stugeron' brand and its key local brands Stugeron FORTE and Stugeron PLUS, along with related assets across 18 markets in the Asia-Pacific (APAC) and Europe, Middle East, and Africa (EMEA) regions, with a focus on India and Vietnam [2] - This deal will enhance Dr. Reddy's Central Nervous System (CNS) portfolio in India and emerging markets by entering the anti-vertigo segment [2] Group 2 - Stugeron contains Cinnarizine, an antihistamine used for treating vestibular disturbances and vertigo [3] - The drug is currently the market leader in the Cinnarizine segment and ranks second in the overall anti-vertigo market segment in India [3]